Modeling and Digital Twins for Process Development, presented

Leachable compounds are currently only evaluated on the toxicological risk they pose to the patient. The effects that leachable compounds have on the quality and safety of pharmaceutical drug products, especially protein drug products, is often overlooked. Interactions of reactive leachable compounds with protein drug products can lead to a loss of efficiency, decrease of stability and increased immunogenicity in the patient population at risk. This webinar describes reactive leachable compounds, the scientific basis to predict leachable-protein interactions and a proof of concept.

Please join S&P Global Ratings leading Chemical analysts for a live interactive webinar on industry trends and the credit outlook for Chemicals. Also, joining the call is our Global Chief Economist Paul Gruenwald who will provide a global economic outlook.

GE Digital Marketing Leader, Laura Foti talks with leaders of the Chemical Industry about using the Industrial Internet of Things to improve safety, increase output, and maximize revenue. Hear from PPG, Accenture, GrayMatter, and Forrester executives on how automating and digitizing processes can remove variability, improve product quality, and ultimately lead to better outcomes for customers.

Recent regulations such as the 2016 amended Toxic Substances Control Act (TSCA) and regulatory agencies such as the European Union (EU) have begun to encourage alternatives to animal testing to assess chemical hazards. These efforts aim to replace animal tests with reliable and validated non-animal methods. This webinar series will highlight the regulatory landscape of toxicity testing requirements and acceptance of animal testing alternatives for industrial chemicals with a specific focus on the 2016 update to TSCA. It will showcase novel and emerging non-animal hazard evaluation strategies for compliance under such regulations such as read-across, high throughput assays, and quantitative structural-activity relationships.